Clinical Trial Update: Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating long-term safety and efficacy of rFIXFc for prevention and treatment of bleeding in previously treated participants with severe …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• rFIXFc (recombinant Factor IX Fc fusion protein)

Snippet

Sponsor: Bioverativ Therapeutics Inc. | Conditions: Severe Hemophilia B | Phase 3 | Status: COMPLETED | Results posted: 2018-11-23